方法：选取2012-05/2015-05在我院接受治疗的严重增生型糖尿病视网膜疾病患者120例120眼，根据病情及患者意愿分为观察组与对照组，每组60例60眼。两组患者在术前均进行超声检查、超声生物显微镜检查、眼底照相、眼压检查等一系列眼部检查。两组患者均行玻璃体切割手术，在此基础上，观察组联合注射雷珠单抗，对照组仅行玻璃体切割手术。

结果：观察组治疗有效率为80.0%，对照组治疗有效率为61.7%。观察组治疗有效率明显高于对照组，差异具有统计学意义(P<0.05)。观察组术后眼压为14.96±3.53mmHg，LogMAR BCVA为0.82±0.21。对照组术后眼压为15.04±3.84mmHg，LogMAR BCVA为1.05±0.22。两组患者治疗后眼压无统计学意义(P>0.05)，LogMAR BCVA与治疗前相比有明显差异，观察组更加明显，具有统计学意义(P<0.05)。两组患者治疗后炎症因子浓度存在显著差异，具有统计学意义(P<0.05)。

结论：玻璃体腔注射雷珠单抗治疗严重增生型糖尿病视网膜病变的临床效果显著，值得推广。

METHODS:The selected 120 patients(120 eyes)with severe proliferative diabetic retinopathy from May 2012 to May 2015 in our hospital were divided into observation group and control group, according to the condition of the disease and the patients' will, 60 cases(60 eyes)in each group. The patients in two groups underwent preoperative ultrasound examination, ultrasound biomicroscopy, fundus photography, tonometry examination and some other ophthalmologic examination. All patients underwent vitrectomy. On this basis, patients in the observation group accepted injection of ranibizumab. The control group only accepted vitrectomy.

RESULTS:The effective rate of observation group was 80.0%, that of the control group was 61.7%. The difference between the two groups was statistically significant(P<0.05). IOP of the observation group was 14.96±3.53mmHg, LogMAR BCVA was 0.82±0.21 after treatments. IOP of the control group was 15.04±3.84mmHg, LogMAR BCVA was 1.05±0.22. There was no significant difference on IOP between the two groups(P>0.05). LogMAR BCVA of the two groups were different compared with those before the treatment and the difference of observation group was more significant(P <0.05). There were significant differences in the two groups after the treatment on concentration of inflammatory cytokines,and the difference was statistically significant(P<0.05).

CONCLUSION:The effect of intravitreal injection of ranibizumab for severe proliferative diabetic retinopathy is significant, worthy of promotion.